Active, not recruitingPhase 2NCT05405361

A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy

Studying Multifocal motor neuropathy

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: argenx
Intervention: ARGX-117(biological)
Enrollment: 51 target
Eligibility: 18 years · All sexes
Timeline: 2023 – 2029

Study locations (27)

HonorHealth Neurology, Scottsdale, Arizona, United States
NorthShore University HealthSystem, Glenview, Illinois, United States
University of Minnesota, Minneapolis, Minnesota, United States
The Cleveland Clinic Foundation, Cleveland, Ohio, United States
University of Pennsylvania - Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States
Austin Neuromuscular Center, Austin, Texas, United States
Medizinische Universitat Wien (Medical University of Vienna), Vienna, Austria
AZ Sint-Lucas, Ghent, Belgium
University Health Network, Toronto, Canada
CHU Bordeaux - Groupe Hospitalier Pellegrin, Bordeaux, France
Hôpital Roger Salengro (CHU de Lille), Lille, France
CHU de Nice, Nice, France
Hôpital de la Pitié Salpétrière, Paris, France
Universitätsklinikum Essen, Essen, Germany
Universitatsmedizin Gottingen (UMG) Georg-August-Universitaet, Göttingen, Germany
+12 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05405361 on ClinicalTrials.gov

Other trials for Multifocal motor neuropathy

Additional recruiting or active studies for the same condition.

See all trials for Multifocal motor neuropathy →

← Back to all trials